Diagnostic and prognostic impact of osteopontin expression in endometrial cancer

Cancer Investigation

Volumn 27, Issue 3, 2009, Pages 313-323

  Cho, HanByoul ^a   Kang, Eun Suk ^b   Kim, Young Tae ^c   Kim, Jae Hoon ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

Author keywords

Diagnostic marker; Endometrial cancer; Osteopontin (OPN); Prognostic marker

Indexed keywords

BIOLOGICAL MARKER; CA 125 ANTIGEN; OSTEOPONTIN; TUMOR MARKER;

ADULT; ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ENDOMETRIUM CANCER; FEMALE; HUMAN; HUMAN TISSUE; HYSTERECTOMY; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PELVIS LYMPHADENECTOMY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SALPINGOOOPHORECTOMY; AGED; BLOOD; ENDOMETRIUM TUMOR; GENETICS; MIDDLE AGED; MORTALITY; POLYMERASE CHAIN REACTION; PROPORTIONAL HAZARDS MODEL;

ADULT; AGED; CA-125 ANTIGEN; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; OSTEOPONTIN; POLYMERASE CHAIN REACTION; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TUMOR MARKERS, BIOLOGICAL;

EID: 63349090034     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900802375738     Document Type: Article

References (49)

1. Jemal, A.; Siegel, R.;Ward, E.; Murray, T.; Xu, J.; Smigal, C.; Thun, M.J. Cancer statistics, 2006. CA Cancer J Clin 2006, 56, 106-130.
2. Jemal, A.; Murray, T.;Ward, E.; Samuels, A.; Tiwari, R.C.; Ghafoor, A.; Feuer, E.J.; Thun, M.J. Cancer statistics, 2005. CA Cancer J Clin 2005, 55, 10-30.
3. Smith, R.A.; Cokkinides, V.; Eyre, H.J. American Cancer Society Guidelines for the Early Detection of Cancer, 2005. CA Cancer J Clin 2005, 55, 31-44; quiz, 55-136
4. Scambia, G.; Benedetti Panici, P.; Baiocchi, G.; Perrone, L.; Greggi, S.; Mancuso, S. CA 15-3 as a tumor marker in gynecological malignancies. Gynecol Oncol. 1988, 30, 265-273. (Pubitemid 18148108)
5. Sood, A.K.; Buller, R.E.; Burger, R.A.; Dawson, J.D.; Sorosky, J.I.; Berman, M. Value of preoperative CA125 level in the management of uterine cancer and prediction of clinical outcome. Obstet Gynecol 1997, 90, 441-447. (Pubitemid 27357939)
6. Dotters, D.J. Preoperative CA125 in endometrial cancer: is it useful? Am J Obstet Gynecol 2000, 182, 1328-1334.
7. Morrow, C.P.; Bundy, B.N.; Kurman, R.J.; Creasman, W.T.; Heller, P.; Homesley, H.D.; Graham, J.E. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol 1991, 40, 55-65.
8. Grigsby, P.W.; Perez, C.A.; Kuten, A.; Simpson, J.R.; Garcia, D.M.; Camel, H.M.; Kao, M.S.; Galakatos, A.E. Clinical stage I endometrial cancer: prognostic factors for local control and distant metastasis and implications of the new FIGO surgical staging system. Int J Radiat Oncol Biol Phys 1992, 22, 905-911.
9. Silverman, M.B.; Roche, P.C.; Kho, R.M.; Keeney, G.L.; Li, H.; Podratz, K.C. Molecular and cytokinetic pretreatment risk assessment in endometrial carcinoma. Gynecol Oncol 2000, 77, 1-7. (Pubitemid 30217297)
10. Salvesen, H.B.; Das, S.; Akslen, L.A. Loss of nuclear p16 protein expression is not associated with promoter methylation but defines a subgroup of aggressive endometrial carcinomas with poor prognosis. Clin Cancer Res 2000, 6, 153-159.
11. Fukuda, K.; Mori, M.; Uchiyama, M.; Iwai, K.; Iwasaka, T.; Sugimori, H. Prognostic significance of progesterone receptor immunohistochemistry in endometrial carcinoma. Gynecol Oncol 1998, 69, 220-225. (Pubitemid 28289963)
12. Salvesen, H.B.; Stefansson, I.; Kalvenes, M.B.; Das, S.; Akslen, L.A. Loss of PTEN expression is associated with metastatic disease in patients with endometrial carcinoma. Cancer 2002, 94, 2185-2191.
13. Nordstrom, B.; Strang, P.; Lindgren, A.; Bergstrom, R.; Tribukait, B. Carcinoma of the endometrium: do the nuclear grade and DNA ploidy provide more prognostic information than do the FIGO and WHO classifications? Int J Gynecol Pathol 1996, 15, 191-201.
14. Oates, A.J.; Barraclough, R.; Rudland, P.S. The role of osteopontin in tumorigenesis and metastasis. Invas Metast 1997, 17, 1-15.
15. Rittling, S.R.; Chambers, A.F. Role of osteopontin in tumour progression. Br J Cancer 2004, 90, 1877-1881.
16. Furger, K.A.; Menon, R.K.; Tuck, A.B.; Bramwell, V.H.; Chambers, A.F. The functional and clinical roles of osteopontin in cancer and metastasis. Curr Mol Med 2001, 1, 621-632. (Pubitemid 33772040)
17. Denhardt, D.T.; Noda, M. Osteopontin expression and function: role in bone remodeling. J Cell Biochem Suppl 1998, 30-31, 92-102. (Pubitemid 29028730)
18. Giachelli, C.M.; Liaw, L.; Murry, C.E.; Schwartz, S.M.; Almeida, M. Osteopontin expression in cardiovascular diseases. Ann N Y Acad Sci 1995, 760, 109-126.
19. Patarca, R.; Freeman, G.J.; Singh, R.P.; Wei, F.Y.; Durfee, T.; Blattner, F.; Regnier, D.C.; Kozak, C.A.; Mock, B.A.; Morse, H.C., 3rd; et al. Structural and functional studies of the early T lymphocyte activation 1 (Eta-1) gene. Definition of a novel T cell-dependent response associated with genetic resistance to bacterial infection. J Exp Med 1989, 170, 145-161.
20. Rittling, S.R.; Denhardt, D.T. Osteopontin function in pathology: lessons from osteopontin-deficient mice. Exp Nephrol 1999, 7, 103-113.
21. Senger, D.R.; Asch, B.B.; Smith, B.D.; Perruzzi, C.A.; Dvorak, H.F. A secreted phosphoprotein marker for neoplastic transformation of both epithelial and fibroblastic cells. Nature 1983, 302, 714-715.
22. Kim, J.H.; Skates, S.J.; Uede, T.; Wong, K.K.; Schorge, J.O.; Feltmate, C.M.; Berkowitz, R.S.; Cramer, D.W.; Mok, S.C. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 2002, 287, 1671-1679. (Pubitemid 34289219)
23. Naish, S.J. Immunochemical Staining Methods. Carpinteria, California, USA: DakoCytomation, 1989.
24. Shijubo, N.; Uede, T.; Kon, S.; Nagata, M.; Abe, S. Vascular endothelial growth factor and osteopontin in tumor biology. Crit Rev Oncog 2000, 11, 135-146.
25. Cao, Q.J.; Belbin, T.; Socci, N.; Balan, R.; Prystowsky, M.B.; Childs, G.; Jones, J.G. Distinctive gene expression profiles by cDNA microarrays in endometrioid and serous carcinomas of the endometrium. Int J Gynecol Pathol 2004, 23, 321-329.
26. Maxwell, G.L.; Chandramouli, G.V.; Dainty, L.; Litzi, T.J.; Berchuck, A.; Barrett, J.C.; Risinger, J.I. Microarray analysis of endometrial carcinomas and mixed mullerian tumors reveals distinct gene expression profiles associated with different histologic types of uterine cancer. Clin Cancer Res 2005, 11, 4056-4066.
27. Risinger, J.I.; Maxwell, G.L.; Chandramouli, G.V.; Jazaeri, A.; Aprelikova, O.; Patterson, T.; Berchuck, A.; Barrett, J.C. Microarray analysis reveals distinct gene expression profiles among different histologic types of endometrial cancer. Cancer Res 2003, 63, 6-11.
28. Saidi, S.A.; Holland, C.M.; Kreil, D.P.; MacKay, D.J.; Charnock-Jones, D.S.; Print, C.G.; Smith, S.K. Independent component analysis of microarray data in the study of endometrial cancer. Oncogene 2004, 23, 6677-6683. (Pubitemid 39265532)
29. Santala, M.; Simojoki, M.; Risteli, J.; Risteli, L.; Kauppila, A. Type I and III collagen metabolites as predictors of clinical outcome in epithelial ovarian cancer. Clin Cancer Res 1999, 5, 4091-4096. (Pubitemid 30013790)
30. Santala, M.; Talvensaari-Mattila, A. DNA ploidy is an independent prognostic indicator of overall survival in stage I endometrial endometrioid carcinoma. Anticancer Res 2003, 23, 5191-5196. (Pubitemid 38182145)
31. Santala, M.; Talvensaari-Mattila, A.; Kauppila, A. Peritoneal cytology and preoperative serum CA125 level are important prognostic indicators of overall survival in advanced endometrial cancer. Anticancer Res 2003, 23, 3097-3103. (Pubitemid 36969868)
32. Niloff, J.M.; Klug, T.L.; Schaetzl, E.; Zurawski, V.R., Jr.; Knapp, R.C.; Bast, R.C., Jr. Elevation of serum CA125 in carcinomas of the fallopian tube, endometrium, and endocervix. Am J Obstet Gynecol 1984, 148, 1057-1058.
33. Duk, J.M.; Aalders, J.G.; Fleuren, G.J.; de Bruijn, H.W. CA125: a useful marker in endometrial carcinoma. Am J Obstet Gynecol 1986, 155, 1097-1102.
34. Patsner, B.; Mann, W.J.; Cohen, H.; Loesch, M. Predictive value of preoperative serum CA125 levels in clinically localized and advanced endometrial carcinoma. Am J Obstet Gynecol 1988, 158, 399-402. (Pubitemid 18064860)
35. Powell, J.L.; Hill, K.A.; Shiro, B.C.; Diehl, S.J.; Gajewski,W.H. Preoperative serum CA-125 levels in treating endometrial cancer. J Reprod Med 2005, 50, 585-590. (Pubitemid 41193137)
36. Prince, C.W.; Oosawa, T.; Butler, W.T.; Tomana, M.; Bhown, A.S.; Bhown, M.; Schrohenloher, R.E. Isolation, characterization, and biosynthesis of a phosphorylated glycoprotein from rat bone. J Biol Chem 1987, 262, 2900-2907.
37. Senger, D.R.; Wirth, D.F.; Hynes, R.O. Transformed mammalian cells secrete specific proteins and phosphoproteins. Cell 1979, 16, 885-893.
38. Liaw, L.; Skinner, M.P.; Raines, E.W.; Ross, R.; Cheresh, D.A.; Schwartz, S.M.; Giachelli,C.M. The adhesive and migratory effects of osteopontin are mediated via distinct cell surface integrins. Role of alpha v beta 3 in smooth muscle cell migration to osteopontin in vitro. J Clin Invest 1995, 95, 713-724.
39. Weber, G.F.; Ashkar, S.; Glimcher,M.J.; Cantor,H. Receptor-ligand interaction between CD44 and osteopontin (Eta-1). Science 1996, 271, 509-512.
40. Fedarko, N.S.; Jain, A.; Karadag, A.; Van Eman, M.R.; Fisher, L.W. Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res 2001, 7, 4060-4066.
41. Wai, P.Y.; Kuo, P.C. The role of osteopontin in tumor metastasis. J Surg Res 2004, 121, 228-241.
42. Senger, D.R.; Perruzzi, C.A.; Gracey, C.F.; Papadopoulos, A.; Tenen, D.G. Secreted phosphoproteins associated with neoplastic transformation: close homology with plasma proteins cleaved during blood coagulation. Cancer Res 1988, 48, 5770-5774.
43. Brown, L.F.; Papadopoulos-Sergiou, A.; Berse, B.; Manseau, E.J.; Tognazzi, K.; Perruzzi, C.A.; Dvorak, H.F.; Senger, D.R. Osteopontin expression and distribution in human carcinomas. Am J Pathol 1994, 145, 610-623. (Pubitemid 24285968)
44. Takemoto, M.; Tada, K.; Nakatsuka, K.; Moriyama, Y.; Kazui, H.; Yokote, K.; Matsumoto, T.; Saito, Y.; Mori, S. [Effects of aging and hyperlipidemia on plasma osteopontin level]. Nippon Ronen Igakkai Zasshi 1999, 36, 799-802.
45. Bautista, D.S.; Saad, Z.; Chambers, A.F.; Tonkin, K.S.; O'Malley, F.P.; Singhal, H.; Tokmakejian, S.; Bramwell, V.; Harris, J.F. Quantification of osteopontin in human plasma with an ELISA: basal levels in pre- and postmenopausal women. Clin Biochem 1996, 29, 231-239.
46. Singhal, H.; Bautista, D.S.; Tonkin, K.S.; O'Malley, F.P.; Tuck, A.B.; Chambers, A.F.; Harris, J.F. Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clin Cancer Res 1997, 3, 605-611.
47. Craig, A.M.; Denhardt, D.T. The murine gene encoding secreted phosphoprotein 1 (osteopontin): promoter structure, activity, and induction in vivo by estrogen and progesterone. Gene 1991, 100, 163-171.
48. Vanacker, J.M.; Pettersson, K.; Gustafsson, J.A.; Laudet, V. Transcriptional targets shared by estrogen receptor-related receptors (ERRs) and estrogen receptor (ER) alpha, but not by ERbeta. EMBO J 1999, 18, 4270-4279. (Pubitemid 29364129)
49. Hall, K.L.; Dewar, M.A.; Perchalski, J. Screening for gynecologic cancer. Vulvar, vaginal, endometrial, and ovarian neoplasms. Prim Care 1992, 19, 607-620.